Will the FDA approve brepocitinib for dermatomyositis by 2026-09-30?

Industry base rate for priority-reviewed NDAs with clean Ph3 in orphan autoimmune is 85-90%. The VALOR dataset (primary + all 9/9 secondary endpoints hit, safety database >1,500 patients) is among the strongest-possible Ph3 packages, arguing for the upper end of the range. Two downward adjustments: (1) strict 2026-09-30 cutoff creates ~8-10% probability of a 3-month PDUFA extension pushing decision into Q4 2026 for label/REMS negotiation (not denial, but resolves NO under the criteria); (2) JAK class boxed-warning negotiation could elevate extension probability modestly. Net 0.80 reflects 0.87 pure approval × 0.92 same-window timing.

Decision tree: P(approve) × P(within 9/30 window). P(approve) ~0.88 given priority review + clean Ph3 + severe unmet need. P(within 9/30 | approved) ~0.88 accounting for typical 15-20% of priority reviews getting 3-month extensions, many of which extend past a given Q3 date. Joint ~0.77. Slight upward adjustment for Priovant's revealed-preference launch preparation (commercial team built, launch materials implied ready for end-September) indicating management has high confidence in on-time PDUFA. Settles at 0.78.

The brepocitinib VALOR package is unusually strong for an orphan autoimmune NDA: largest/longest DM trial ever (N=241), first positive 52-week placebo-controlled study, hit primary and 9/9 secondary endpoints with statistical significance, safety database >1,500 patients. This package is closer to a 'rubber-stamp' approval than a borderline case. The 85-90% base rate applied to typical priority reviews likely understates the true probability here (closer to 90-92%). Downward adjustment of ~10 points for 9/30 cutoff timing (PDUFA could be set as late as Sept 29 with no buffer for minor delays). Net 0.82.

The approval leg is high-confidence favorable (base rate 85-90% applied to clean data package). The timing leg is the source of uncertainty: PDUFA extensions are common for JAK class label negotiation (15-20% of priority reviews), and the 9/30 strict cutoff mechanically resolves NO if FDA uses extension even briefly. Additionally, AdCom possibility remains open per Regulatory Reader data gap — if AdCom is announced it further compresses timing. Joint estimate: 0.87 × 0.87 = 0.76.

Strong Ph3 package + Priority Review + orphan disease with severe unmet need + no disclosed AdCom 5 months out + brepocitinib safety database >1,500 patients all support high approval probability. The main discount is timing precision rather than approval itself. PDUFA target 'Q3 CY2026' could mean any date from July to September; if FDA sets it at end-September, any operational delay pushes resolution past 9/30. Probability 0.79 reflects ~0.90 approval × ~0.88 same-window.

Conservative version of the case. While clean Ph3 data supports high approval probability, several risks compress the 9/30 resolution: (1) JAK class boxed-warning negotiation commonly triggers PDUFA extension; (2) Priovant is a small private-vantage entity reliant on ROIV-PFE partnership and has not previously piloted a commercial drug through FDA approval — administrative coordination risk; (3) post-batoclimab narrative pressure may mildly elevate FDA scrutiny. Base rate 85-90% approval × 85% same-window timing = 0.72-0.76. Settle at 0.75.

Priority Review + clean VALOR Ph3 (primary + 9/9 secondary) + severe unmet need + safety database >1,500 patients → approval probability ~85-90%. Discount for 2026-09-30 strict timing cutoff (~8-10%) and JAK label negotiation (~5%). Net 0.80.

Base rate 85-90% approval for priority-reviewed orphan autoimmune with clean Ph3 data. VALOR results are clean. Two timing risks: (1) 9/30 strict cutoff with typical Q3 PDUFA dates late in quarter, (2) PDUFA extension rate 15-20% for label negotiation. Net 0.77.

Strong approval case: Priority Review + clean VALOR + severe unmet need. Base rate 85-90%. Modest discount for 9/30 cutoff (~8%) and label negotiation timing. Net 0.80.